Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 3/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448260 | 1.00 | FUCA1 (0.37) | FUCA1ALDH1A1HTR2BKMT2APYGL | |
| SCHEMBL27947078 | 0.76 | P2RX7 (0.36) | ALDH1A1POLB | |
| SCHEMBL27947079 | 0.76 | P2RX7 (0.36) | ALDH1A1POLB | |
| SCHEMBL12466995 | 0.74 | HTR2B (0.38) | ALDH1A1HTR2BKMT2APYGLL3MBTL1 | |
| SCHEMBL20119105 | 0.73 | KDM1A (0.42) | KMT2A | |
| SCHEMBL18589010 | 0.73 | KDM1A (0.42) | KMT2A | |
| Hydrochloric Acid SCHEMBL15016945 | 0.72 | KDM1A (0.41) | KMT2A | |
| Hydrochloric Acid SCHEMBL15016947 | 0.72 | KDM1A (0.41) | KMT2A | |
| SCHEMBL6415801 | 0.70 | ALDH1A1 (0.58) | ALDH1A1ALOX5GAAL3MBTL1 | |
| SCHEMBL445829 | 0.70 | NTRK1 (0.37) | HTR2BJAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2678338-B1 | PYRAZOLO[1,5-A]PYRIDINES AS TRK INHIBITORS | NOVARTIS AG (CH) | 2015-09-09 | — | — | EP | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102671-B2 | Compounds and compositions as TRK inhibitors | NOVARTIS AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| EP-2678338-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| EP-2614062-A1 | IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116217-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-08-30 | — | — | WO | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331397-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | CNKSR1, BMP2K, RAF1 | FUCA1 4245/4885ALDH1A1 4150/4885HTR2B 4229/4885 |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | FUCA1 4018/4885ALDH1A1 4129/4885HTR2B 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.